Evidence map›Paper›PMID 31252688›Full record

ReviewCancers2019

miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis.

Madhav Madurantakam Royam, Rithika Ramesh, Ritika Shanker, Shanthi Sabarimurugan, Chellan Kumarasamy, Nachimuthu Ramesh, Kodiveri Muthukalianan Gothandam, Siddharta Baxi, Ajay Gupta, Sunil Krishnan and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Mapping Research on miRNAs in Cancer: A Global Data Analysis and Bibliometric Profiling Analysis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Chemoresistance in Pancreatic Cancer.International journal of molecular sciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Madhav Madurantakam RoyamSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.ORCID 0000-0002-7885-460X
Rithika RameshSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.
Ritika ShankerSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.
Shanthi SabarimuruganSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.ORCID 0000-0003-2247-3426
Chellan KumarasamyUniversity of Adelaide, Adelaide, SA 5005, Australia.
Nachimuthu RameshSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.
Kodiveri Muthukalianan GothandamSchool of Biosciences and Technology, Vellore Institute of Technology (VIT), Vellore 632014, India.ORCID 0000-0003-1576-5324
Siddharta BaxiGenesis Cancer Care Centre, Bunbury, WA 6014, Australia.
Ajay GuptaNational Heart Institute, New Delhi 110065, India.
Sunil KrishnanDepartment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Rama JayarajCollege of Health and Human Sciences, Yellow 1.1.05, Ellengowan Drive, Charles Darwin University, Darwin, NT 0909, Australia. Rama.Jayaraj@cdu.edu.au.ORCID 0000-0002-2179-0510

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundpancreatic cancer (PC) has increasing incidence and mortality in developing countries, and drug resistance is a significant hindrance to the efficacy of successful treatment. The objective of this systematic review and meta-analysis was to evaluate the association between miRNAs and response to chemotherapy in pancreatic cancer patients.

methodsthe systematic review and meta-analysis was based on articles collected from a thorough search of PubMed and Science Direct databases for publications spanning from January 2008 to December 2018. The articles were screened via a set of inclusion and exclusion criteria based on the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. Data was extracted, collated and tabulated in MS Excel for further synthesis. Hazard ratio (HR) was selected as the effect size metric to be pooled across studies for the meta-analysis, with the random effects model being applied. Subgroup analysis was also conducted, and the presence of publication bias in the selected studies was assessed. Publication bias of the included studies was quantified.

findingsof the 169 articles screened, 43 studies were included in our systematic review and 13 articles were included in the meta-analysis. Gemcitabine was observed to be the principal drug used in a majority of the studies. A total of 48 miRNAs have been studied, and 18 were observed to have possible contributions to chemoresistance, while 15 were observed to have possible contributions to chemosensitivity. 41 drug-related genetic pathways have been identified, through which the highlighted miRNA may be affecting chemosensitivity/resistance. The pooled HR value for overall survival was 1.603; (95% Confidence Interval (CI) 1.2-2.143;

interpretationour results highlight multiple miRNAs that have possible associations with modulation of chemotherapy response in pancreatic cancer patients. Further studies are needed to discover the molecular mechanisms underlying these associations before they can be suggested for use as biomarkers of response to chemotherapeutic interventions in pancreatic cancer.

Indexed as

chemoresistancemeta-analysismiRNAspancreatic cancersystematic review

Identifiers

PMID31252688
PMCPMC6678460

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.